PDS Biotechnology (NASDAQ: PDSB) — Company Overview, News & Financial Data
PDS Biotechnology develops immunotherapies for cancer and infectious diseases, utilizing its proprietary Versamune® platform.
PDS Biotechnology
PDS Biotechnology (NASDAQ:PDSB) specializes in the development of immunotherapies to fight various types of cancer and infectious diseases. Central to its operations is the Versamune® platform, a proprietary technology designed to activate the body's immune response towards specific diseases. PDS Biotechnology is currently focused on advancing its pipeline, including lead candidates for treating HPV-associated cancers and a collaboration for a COVID-19 vaccine. The company's objective is to deliver innovative treatments that improve patient outcomes and address unmet medical needs by harnessing the power of the immune system.
Snapshot
Operations
Products and/or services of PDS Biotechnology
- Versamune® technology, a platform aimed at advancing immune-activating therapies for cancer.
- PDS0101, a therapeutic vaccine targeting HPV-related cancers.
- Combination therapies leveraging PDS0101 for more effective cancer treatment options.
- Development of vaccines for infectious diseases utilizing Versamune® and other proprietary technologies.
- Research into novel immunotherapies aiming to treat a broader range of cancers.
- Collaboration with pharmaceutical companies to enhance and co-develop the existing pipeline of cancer immunotherapies.
PDS Biotechnology executive team
- Frank K. Bedu-AddoFounder, President, CEO, Interim CFO & Director
- Kirk V. ShepardChief Medical Officer
- Janetta TrochimiukController & Interim Principal Accounting Officer
- Gregory L. ConnChief Scientific Officer
- Spencer BrownSenior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Latest news about PDS Biotechnology
Key financials
Reported results for PDS Biotechnology , in USD.
- Market cap
- 162.8M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.7
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -31.5M | -34.5M | |
| 0 | -36.3M | -37.6M | |
| 0 | -43M | -42.9M | |
| 0 | -41.7M | -40.9M |